US20040129737A1 - Valves for use in containers having valve stems slidably movable within round-edged sealing rings - Google Patents
Valves for use in containers having valve stems slidably movable within round-edged sealing rings Download PDFInfo
- Publication number
- US20040129737A1 US20040129737A1 US10/739,664 US73966403A US2004129737A1 US 20040129737 A1 US20040129737 A1 US 20040129737A1 US 73966403 A US73966403 A US 73966403A US 2004129737 A1 US2004129737 A1 US 2004129737A1
- Authority
- US
- United States
- Prior art keywords
- valve
- sealing ring
- stem
- valve according
- moulding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000007789 sealing Methods 0.000 title claims abstract description 77
- 239000000443 aerosol Substances 0.000 claims abstract description 13
- 238000004891 communication Methods 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims description 21
- -1 polypropylene Polymers 0.000 claims description 21
- 238000000465 moulding Methods 0.000 claims description 18
- 239000000314 lubricant Substances 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 229920002725 thermoplastic elastomer Polymers 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 7
- 239000013536 elastomeric material Substances 0.000 claims description 7
- 239000003380 propellant Substances 0.000 claims description 7
- 238000005070 sampling Methods 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 229920002943 EPDM rubber Polymers 0.000 claims description 6
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 6
- 229960002052 salbutamol Drugs 0.000 claims description 6
- 229960004017 salmeterol Drugs 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 6
- 239000004743 Polypropylene Substances 0.000 claims description 5
- 229920001155 polypropylene Polymers 0.000 claims description 5
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 claims description 4
- LIKMAJRDDDTEIG-UHFFFAOYSA-N 1-hexene Chemical compound CCCCC=C LIKMAJRDDDTEIG-UHFFFAOYSA-N 0.000 claims description 4
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical compound CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 claims description 4
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 4
- 229950000210 beclometasone dipropionate Drugs 0.000 claims description 4
- 238000000748 compression moulding Methods 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 229960000289 fluticasone propionate Drugs 0.000 claims description 4
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 4
- 238000001746 injection moulding Methods 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 238000001721 transfer moulding Methods 0.000 claims description 4
- 229960001361 ipratropium bromide Drugs 0.000 claims description 3
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005977 Ethylene Substances 0.000 claims description 2
- 229920001400 block copolymer Polymers 0.000 claims description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 2
- 229920005996 polystyrene-poly(ethylene-butylene)-polystyrene Polymers 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229920001971 elastomer Polymers 0.000 description 16
- 239000005060 rubber Substances 0.000 description 12
- 239000000806 elastomer Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229920001169 thermoplastic Polymers 0.000 description 4
- 239000000956 alloy Substances 0.000 description 3
- 229910045601 alloy Inorganic materials 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229920002313 fluoropolymer Polymers 0.000 description 3
- 239000004416 thermosoftening plastic Substances 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- MSKQYWJTFPOQAV-UHFFFAOYSA-N fluoroethene;prop-1-ene Chemical group CC=C.FC=C MSKQYWJTFPOQAV-UHFFFAOYSA-N 0.000 description 2
- 239000004811 fluoropolymer Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229920001084 poly(chloroprene) Polymers 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229920001187 thermosetting polymer Polymers 0.000 description 2
- 229950000339 xinafoate Drugs 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- UBLVUWUKNHKCJJ-ZSCHJXSPSA-N (2s)-2,6-diaminohexanoic acid;1,3-dimethyl-7h-purine-2,6-dione Chemical compound NCCCC[C@H](N)C(O)=O.O=C1N(C)C(=O)N(C)C2=C1NC=N2 UBLVUWUKNHKCJJ-ZSCHJXSPSA-N 0.000 description 1
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- VHOQXEIFYTTXJU-UHFFFAOYSA-N Isobutylene-isoprene copolymer Chemical compound CC(C)=C.CC(=C)C=C VHOQXEIFYTTXJU-UHFFFAOYSA-N 0.000 description 1
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 229920000459 Nitrile rubber Polymers 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- 229920002614 Polyether block amide Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 229920005557 bromobutyl Polymers 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229920005556 chlorobutyl Polymers 0.000 description 1
- 229960003821 choline theophyllinate Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 238000002788 crimping Methods 0.000 description 1
- 229940109248 cromoglycate Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001268 isoetarine Drugs 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 229920003049 isoprene rubber Polymers 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 1
- 229960001869 methapyrilene Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- 229960000797 oxitropium Drugs 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- RLANKEDHRWMNRO-UHFFFAOYSA-M oxtriphylline Chemical compound C[N+](C)(C)CCO.O=C1N(C)C(=O)N(C)C2=C1[N-]C=N2 RLANKEDHRWMNRO-UHFFFAOYSA-M 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001021 polysulfide Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920003225 polyurethane elastomer Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 229960002720 reproterol Drugs 0.000 description 1
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229960001457 rimiterol Drugs 0.000 description 1
- IYMMESGOJVNCKV-SKDRFNHKSA-N rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 description 1
- 229950004432 rofleponide Drugs 0.000 description 1
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 description 1
- 229960005018 salmeterol xinafoate Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
- 229940110309 tiotropium Drugs 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960000859 tulobuterol Drugs 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/14—Containers or packages with special means for dispensing contents for delivery of liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant for a product delivered by a propellant
- B65D83/44—Valves specially adapted therefor; Regulating devices
- B65D83/48—Lift valves, e.g. operated by push action
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/14—Containers or packages with special means for dispensing contents for delivery of liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant for a product delivered by a propellant
- B65D83/44—Valves specially adapted therefor; Regulating devices
- B65D83/52—Valves specially adapted therefor; Regulating devices for metering
- B65D83/54—Metering valves ; Metering valve assemblies
Definitions
- This invention relates to a valve for an aerosol container with the aid of which a quantity of the contents thereof can be dispensed.
- the invention has particular application to the dispensing of metered doses of medicaments, though it is applicable to the dispensing of aerosols generally.
- Containers for aerosol formulations commonly comprise a vial body coupled to a valve.
- the valve comprises a valve stem through which the formulation is dispensed.
- the valve includes a rubber valve seal intended to allow reciprocal movement of the valve stem while preventing leakage of propellant from the container.
- valve stem tends to stick, pause, or drag during the actuation cycle with the result that the valve stem may not move smoothly, particularly when released. This may be partly caused by the drug sedimenting or precipitating out of the drug-propellant suspension or solution formulation and depositing on the internal valve components, the presence of drug on the sliding interface creating increased friction during operation.
- Prior art seals generally comprise a rubber ring formed by stamping out a ring shape from a sheet of rubber material.
- the ring aperture thus, inevitably has square-cut edges which present a relatively high area of contact between the seal and the stem. Furthermore, when the valve stem is moved in such square-cut seals the seal deforms in such a way that the surface area, and hence the frictional contact area, between the seal and stem increases.
- valve seal is shaped such as to reduce the area of contact between the seal and the stem.
- a ring may be formed having a ring aperture with rounded or otherwise shaped edges.
- the area of contact between the seal and the stem is less than that for a ring of equivalent thickness having square-cut edges.
- the seal On movement of the stem within the seal there is also less tendency for the seal to deform such as to increase the contact area between the seal and the stem.
- a valve for an aerosol container comprising a valve body; within said valve body, a sealing ring; and receivable by said sealing ring, a valve stem having a dispensing passage, the valve stem being slidably movable within the sealing ring from a valve-closed position to a valve-open position in which the interior of the valve body is in communication with the dispensing passage, wherein the sealing ring is shaped such as to reduce the contact area between the sealing ring and the valve stem.
- the area of contact between the sealing ring and the valve stem is less than 90%, more preferably less than 70%, most preferably less than 50% of what the area of contact would be if the stem-receiving aperture of the sealing ring had square-cut edges.
- the sealing ring is formable by a moulding process.
- the moulding process is injection moulding.
- the moulding process is compression moulding.
- the moulding process is transfer moulding.
- the sealing ring is not movable relative to the valve body, that is to say it is somehow fixed thereto. More preferably, the sealing ring is held within a cavity in the valve body.
- the stem-receiving part of the sealing ring has at least one rounded edge, preferably all stem-receiving edges are rounded.
- the stem-receiving part of the sealing ring presents a lobed surface to the stern. That is to say the surface comprises one or more lobe features.
- the lobed surface and the stem-receiving part of the stem define one or more wells. More preferably, the one or more wells contain lubricant material therein.
- the valve is a metering valve in which the valve body has a metering chamber, a sampling chamber and therebetween is provided a second sealing ring within which the stem is slidably movable, the valve stem having a transfer passage such that in the valve-closed position the dispensing passage is isolated from the metering chamber and the metering chamber is in communication with the sampling chamber via said transfer passage, and in the valve-open position the dispensing passage is in communication with the metering chamber and the transfer passage is isolated from the metering chamber, wherein the second sealing ring is shaped such as to reduce the contact area between the second sealing ring and the valve stem.
- the area of contact between the second sealing ring and the valve stem is less than 90%, more preferably less than 70%, most preferably less than 50% of what the area of contact would be if the stem-receiving aperture of the second sealing ring had square-cut edges.
- the sealing ring and any second sealing ring is formable by a moulding process.
- the moulding process is injection moulding.
- the moulding process is compression moulding.
- the moulding process is transfer moulding.
- the second sealing ring is not movable relative to the valve body.
- the second sealing ring is held within a cavity in the valve body.
- the stem-receiving part of the second sealing ring has at least one rounded edge, preferably all stem-receiving edges are rounded.
- the stem-receiving part of the second sealing ring presents a lobed surface to the stem.
- the lobed surface and the stem-receiving part of the stem define one or more wells. More preferably, the one or more wells contain lubricant material therein.
- the sealing ring and/or second sealing ring comprises an elastomeric material.
- the ring is typically resiliently deformable.
- the elastomeric material may either comprise a thermoplastic elastomer (TPE) or a thermoset elastomer which may optionally be cross-linked.
- the sealing ring may also comprise a thermoplastic elastomer blend or alloy in which an elastomeric material is dispersed in a thermoplastic matrix.
- the elastomers may optionally additionally contain conventional polymer additives such as processing aids, colorants, tackifiers, lubricants, silica, talc, or processing oils such as mineral oil in suitable amounts.
- thermoset rubbers include butyl rubbers, chloro-butyl rubbers, bromo-butyl rubbers, nitrile rubbers, silicone rubbers, flurosilicone rubbers, fluorocarbon rubbers, polysulphide rubbers, polypropylene oxide rubbers, isoprene rubbers, isoprene-isobutene rubbers, isobutylene rubbers or neoprene (polychloroprene) rubbers.
- Suitable thermoplastic elastomers comprise a copolymer of about 80 to about 95 mole percent ethylene and a total of about 5 to about 20 mole percent of one or more comonomers selected from the group consisting of 1-butene, 1-hexene, and 1-octene as known in the art. Two or more such copolymers may be blended together to form a thermoplastic polymer blend.
- thermoplastic elastomers are the styrene-ethylene/butylene-styrene block copolymers. These copolymers may additionally comprise a polyolefin (e.g. polypropylene) and a siloxane.
- a polyolefin e.g. polypropylene
- siloxane e.g. siloxane
- Thermoplastic elastomeric material may also be selected from one or more of the following: polyester rubbers, polyurethane rubbers, ethylene vinyl acetate rubber, styrene butadiene rubber, copolyether ester TPE, olefinic TPE, polyester amide TPE and polyether amide TPE.
- EPDM ethylene propylene diene rubber
- the EPDM may be present on its own or present as part of a thermoplastic elastomer blend or alloy, e.g. in the form of particles substantially uniformly dispersed in a continuous thermoplastic matrix (e.g. polypropylene or polyethylene).
- a continuous thermoplastic matrix e.g. polypropylene or polyethylene.
- thermoplastic elastomer blend and alloys include the SANTOPRENETM elastomers.
- Other suitable thermoplastic elastomer blends include butyl-polyethylene (e.g. in a ratio ranging between about 2:3 and about 3:2) and butyl-polypropylene.
- the sealing ring and/or the second sealing ring additionally comprises lubricant material.
- the sealing ring and/or the second sealing ring comprises up to 30%, preferably from 5 to 20% lubricant material.
- the stem comprises lubricant material.
- the valve stem comprises up to 30%, preferably from 5 to 20% lubricant material.
- lubricant herein means any material which reduces friction between the valve stem and seal. Suitable lubricants include silicone oil or a fluorocarbon polymer such as polytetrafluoroethane (PTFE) or fluoroethylene propylene (FEP).
- PTFE polytetrafluoroethane
- FEP fluoroethylene propylene
- Lubricant can be applied to the stem, sealing ring or second sealing ring by any suitable process including coating and impregnation, such as by injection or a tamponage process.
- an aerosol container comprising a valve as described hereinabove.
- the aerosol container comprises a suspension of a medicament in a propellant.
- the propellant is liquefied HFA134a or HFA-227 or mixtures thereof.
- the medicament is selected from albuterol, salmeterol, fluticasone propionate, beclomethasone dipropionate and ipratropium bromide and salts or solvates thereof and any combination thereof.
- FIG. 1 is a section through a metering valve according to the invention
- FIG. 2 is a close-up sectional view of a seal-stem contact point in a valve according to the invention
- FIG. 3 is a close-up sectional view of a seal-stem contact point in a valve according to the invention.
- FIG. 4 a is a close-up sectional view of a seal-stem contact point in a prior art valve in a rest position
- FIG. 4 b is a close-up sectional view of a seal-stem contact point in the valve of FIG. 4 a in an active position.
- a valve according to the invention is shown in FIG. 1 and comprises a valve body 1 sealed in a ferrule 2 by means of crimping, the ferrule itself being set on the neck of a container (not shown) with interposition of a gasket 3 in a well-known manner.
- the container is loadable with a suspension of medicament, such as salmeterol xinafoate in liquid propellant HFA134a.
- the valve body 1 is formed at its lower part with a metering chamber 4 , and its upper part with a sampling chamber 5 which also acts as a housing for a return spring 6 .
- the words “upper” and “lower” are used for the container when it is in a use orientation with the neck of the container and valve at the lower end of the container which corresponds to the orientation of the valve as shown in FIG. 1.
- Inside the valve body 1 is disposed a valve stem 7 , a part 8 of which extends outside the valve through lower stem seal 9 and ferrule 2 .
- the stem part 8 is formed with an inner axial or longitudinal canal 10 opening at the outer end of the stem and in communication with a radial passage 11 .
- the upper portion of stem 7 has a diameter such that it can pass slidably through an opening in an upper stem seal 12 and will engage the periphery of that opening sufficiently to provide a seal.
- the stem seals 9 and 12 are made by a moulding process and have rounded points of contact with the valve stem 7 .
- Upper stem seal 12 is held in position against a step 13 formed in the valve body 1 between the said lower and upper parts by a sleeve 14 which defines the metering chamber 4 between lower stem seal 9 and upper stem seal 12 .
- the valve stem 7 has a passage 15 which, when the stem is in the inoperative position shown, provides a communication between the metering chamber 4 and sampling chamber 5 , which itself communicates with the interior of the container via orifice 16 formed in the side of the valve body 1 .
- Valve stem 7 is biased downwardly to the inoperative position by return spring 6 and is provided with a shoulder 17 which abuts against lower stem seal 9 .
- shoulder 17 In the inoperative position as shown in FIG. 1 shoulder 17 abuts against lower stem seal 9 and radial passage 11 opens below lower stem seal 9 so that the metering chamber 4 is isolated from canal 10 and suspension inside cannot escape.
- a ring 18 having a “U” shaped cross section extending in a radial direction is disposed around the valve body below orifice 16 so as to form a trough 19 around the valve body.
- the ring is formed as a separate component having an inner annular contacting rim of a diameter suitable to provide a friction fit over the upper part of valve body 1 , the ring seating against step 13 below the orifice 16 .
- the ring 18 may alternatively be formed as an integrally moulded part of valve body 1 .
- the container is first shaken to homogenise the suspension within the container.
- the user then depresses the valve stem 7 against the force of the spring 6 .
- both ends of the passage 15 come to lie on the side of upper stem seal 12 remote from the metering chamber 4 .
- a dose is metered within the metering chamber.
- Continued depression of the valve stem will move the radial passage 11 into the metering chamber 4 while the upper stem seal 12 seals against the valve stem body.
- the metered dose can exit through the radial passage 11 and the outlet canal 10 .
- FIG. 2 shows a cut-away detail of a seal-stem contact point of a valve herein.
- the upright valve stem 108 which has a circular cross-section is sealingly contacted by a sealing ring 112 .
- the ring aperture 130 of the sealing ring 112 has rounded edges. It may be understood that the area of contact of the ring 112 with the stem 108 is less than it would be if the ring 112 had square-cut edges. When the stem 108 is moved upwards, the ring 112 will tend to flex into free-space 140 .
- FIG. 3 shows a cut-away detail of a seal-stem contact point of a second valve herein.
- the upright valve stem 208 which has a circular cross-section is sealingly contacted by a sealing ring 212 .
- the ring aperture of the sealing ring 212 is edged by two rounded lobes 230 , 232 .
- the area of contact of the ring 212 with the stem 208 is less than it would be if the ring 212 had square-cut edges.
- the well 242 may be wholly or partially filled with a lubricant material.
- FIGS. 4 a and 4 b show a cut-away detail of a seal-stem contact point of a prior art valve, wherein FIG. 4 a shows a rest configuration and FIG. 4 b shows the configuration when the valve is in an active position.
- the upright valve stem 308 which has a circular cross-section is sealingly contacted by a sealing ring 312 .
- the ring aperture 330 of the sealing ring 312 has square-cut edges 330 .
- sealing ring a number of different configurations of the sealing ring are possible, in addition to those described in FIGS. 2 and 3, in which the contact area between the sealing ring and the valve stem is reduced.
- One possible configuration is similar to that shown in FIG. 3 but the ring aperture is edged by more than 2 lobes.
- Another possible configuration has a sealing ring aperture with straight tapered edges leading to a point (such that its cross section is triangular in shape) which has reduced contact with the valve stem compared to straight cut edges.
- a lobed version of this sealing ring is also possible wherein there are two or more lobes each tapered to a point.
- a further configuration which reduces the contact area with the valve stem has sections of the top and bottom sides of the ring aperture cut away to leave a smaller projecting portion to form a seal with the valve stem.
- the projecting portion may have straight cut or shaped edges. Cutting one or more grooves or small channels in the non stem-receiving surfaces of the sealing ring provides space for the stem-receiving part of the sealing ring to move into upon movement of the valve stem, resulting in reduced deformation and friction at the contact surface with the valve stem.
- any of the parts of the metering valve which contact the medicament suspension may be coated with materials such as fluoropolymer materials which reduce the tendency of medicament to adhere thereto.
- Suitable fluoropolymers include polytetrafluoroethylene (PTFE) and fluoroethylene propylene (FEP).
- PTFE polytetrafluoroethylene
- FEP fluoroethylene propylene
- Any movable parts may also have coatings applied thereto which enhance their desired movement characteristics. Frictional coatings may therefore be applied to enhance frictional contact and lubricants used to reduce frictional contact as necessary.
- the aerosol container and valve of the invention is suitable for dispensing medicament, particularly for the treatment of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD).
- respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD).
- COPD chronic obstructive pulmonary disease
- Appropriate medicaments may thus be selected from, for example, analgesics, e.g., codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g., diltiazem; antiallergics, e.g., cromoglycate, ketotifen or nedocromil; antiinfectives e.g., cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, e.g., methapyrilene; anti-inflammatories, e.g., beclomethasone dipropionate, fluticasone propionate, flunisolide, budesonide, rofleponide, mometasone furoate or triamcinolone acetonide; antitussives, e.g., noscapine
- the medicaments may be used in the form of salts, (e.g., as alkali metal or amine salts or as acid addition salts) or as esters (e.g., lower alkyl esters) or as solvates (e.g., hydrates) to optimise the activity and/or stability of the medicament.
- salts e.g., as alkali metal or amine salts or as acid addition salts
- esters e.g., lower alkyl esters
- solvates e.g., hydrates
- Preferred medicaments are selected from albuterol, salmeterol, fluticasone propionate and beclomethasone dipropionate, and ipratropium bromide and salts or solvates thereof, e.g., the sulphate of albuterol and the xinafoate of salmeterol.
- Medicaments can also be delivered in combinations.
- Preferred formulations containing combinations of active ingredients contain salbutamol (e.g., as the free base or the sulphate salt) or salmeterol (e.g., as the xinafoate salt) in combination with an anti-inflammatory steroid such as a beclomethasone ester (e.g., the dipropionate) or a fluticasone ester (e.g., the propionate).
- an anti-inflammatory steroid such as a beclomethasone ester (e.g., the dipropionate) or a fluticasone ester (e.g., the propionate).
Landscapes
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
Abstract
There is provided a valve for an aerosol container. The valve comprises a valve body; within the valve body, a sealing ring and receivable by the sealing ring, a valve stem having a dispensing passage. The valve stem is slidably movable within the sealing ring from a valve-closed position to a valve-open position in which the interior of the valve body is in communication with the dispensing passage. The sealing ring is shaped such as to reduce the contact area between the sealing ring and the valve stem. Preferably, the valve is a metering valve.
Description
- This invention relates to a valve for an aerosol container with the aid of which a quantity of the contents thereof can be dispensed. The invention has particular application to the dispensing of metered doses of medicaments, though it is applicable to the dispensing of aerosols generally.
- Containers for aerosol formulations commonly comprise a vial body coupled to a valve. The valve comprises a valve stem through which the formulation is dispensed. Generally the valve includes a rubber valve seal intended to allow reciprocal movement of the valve stem while preventing leakage of propellant from the container.
- It has been found that in some conventional devices the valve stem tends to stick, pause, or drag during the actuation cycle with the result that the valve stem may not move smoothly, particularly when released. This may be partly caused by the drug sedimenting or precipitating out of the drug-propellant suspension or solution formulation and depositing on the internal valve components, the presence of drug on the sliding interface creating increased friction during operation.
- Prior art seals generally comprise a rubber ring formed by stamping out a ring shape from a sheet of rubber material. The ring aperture, thus, inevitably has square-cut edges which present a relatively high area of contact between the seal and the stem. Furthermore, when the valve stem is moved in such square-cut seals the seal deforms in such a way that the surface area, and hence the frictional contact area, between the seal and stem increases.
- The Applicants have now found that the above described problem may be ameliorated without compromising sealing performance if the valve seal is shaped such as to reduce the area of contact between the seal and the stem. If a manufacturing process based upon moulding is employed a ring may be formed having a ring aperture with rounded or otherwise shaped edges. When such a rounded or shaped-edge ring is used as a valve seal the area of contact between the seal and the stem is less than that for a ring of equivalent thickness having square-cut edges. On movement of the stem within the seal there is also less tendency for the seal to deform such as to increase the contact area between the seal and the stem.
- According to the present invention there is provided a valve for an aerosol container, the valve comprising a valve body; within said valve body, a sealing ring; and receivable by said sealing ring, a valve stem having a dispensing passage, the valve stem being slidably movable within the sealing ring from a valve-closed position to a valve-open position in which the interior of the valve body is in communication with the dispensing passage, wherein the sealing ring is shaped such as to reduce the contact area between the sealing ring and the valve stem.
- Preferably, the area of contact between the sealing ring and the valve stem is less than 90%, more preferably less than 70%, most preferably less than 50% of what the area of contact would be if the stem-receiving aperture of the sealing ring had square-cut edges.
- Preferably, the sealing ring is formable by a moulding process.
- Preferably, the moulding process is injection moulding.
- Alternatively, the moulding process is compression moulding.
- Alternatively, the moulding process is transfer moulding.
- Preferably, the sealing ring is not movable relative to the valve body, that is to say it is somehow fixed thereto. More preferably, the sealing ring is held within a cavity in the valve body.
- In one aspect, the stem-receiving part of the sealing ring has at least one rounded edge, preferably all stem-receiving edges are rounded.
- In another aspect, the stem-receiving part of the sealing ring presents a lobed surface to the stern. That is to say the surface comprises one or more lobe features. Preferably, the lobed surface and the stem-receiving part of the stem define one or more wells. More preferably, the one or more wells contain lubricant material therein.
- Preferably, the valve is a metering valve in which the valve body has a metering chamber, a sampling chamber and therebetween is provided a second sealing ring within which the stem is slidably movable, the valve stem having a transfer passage such that in the valve-closed position the dispensing passage is isolated from the metering chamber and the metering chamber is in communication with the sampling chamber via said transfer passage, and in the valve-open position the dispensing passage is in communication with the metering chamber and the transfer passage is isolated from the metering chamber, wherein the second sealing ring is shaped such as to reduce the contact area between the second sealing ring and the valve stem.
- Preferably, the area of contact between the second sealing ring and the valve stem is less than 90%, more preferably less than 70%, most preferably less than 50% of what the area of contact would be if the stem-receiving aperture of the second sealing ring had square-cut edges.
- Preferably, the sealing ring and any second sealing ring is formable by a moulding process.
- Preferably, the moulding process is injection moulding.
- Alternatively, the moulding process is compression moulding.
- Alternatively, the moulding process is transfer moulding.
- Preferably, the second sealing ring is not movable relative to the valve body.
- More preferably, the second sealing ring is held within a cavity in the valve body.
- In one aspect, the stem-receiving part of the second sealing ring has at least one rounded edge, preferably all stem-receiving edges are rounded.
- In another aspect, the stem-receiving part of the second sealing ring presents a lobed surface to the stem. Preferably, the lobed surface and the stem-receiving part of the stem define one or more wells. More preferably, the one or more wells contain lubricant material therein.
- Preferably the sealing ring and/or second sealing ring comprises an elastomeric material. The ring is typically resiliently deformable.
- The elastomeric material may either comprise a thermoplastic elastomer (TPE) or a thermoset elastomer which may optionally be cross-linked. The sealing ring may also comprise a thermoplastic elastomer blend or alloy in which an elastomeric material is dispersed in a thermoplastic matrix. The elastomers may optionally additionally contain conventional polymer additives such as processing aids, colorants, tackifiers, lubricants, silica, talc, or processing oils such as mineral oil in suitable amounts.
- Suitable thermoset rubbers include butyl rubbers, chloro-butyl rubbers, bromo-butyl rubbers, nitrile rubbers, silicone rubbers, flurosilicone rubbers, fluorocarbon rubbers, polysulphide rubbers, polypropylene oxide rubbers, isoprene rubbers, isoprene-isobutene rubbers, isobutylene rubbers or neoprene (polychloroprene) rubbers.
- Suitable thermoplastic elastomers comprise a copolymer of about 80 to about 95 mole percent ethylene and a total of about 5 to about 20 mole percent of one or more comonomers selected from the group consisting of 1-butene, 1-hexene, and 1-octene as known in the art. Two or more such copolymers may be blended together to form a thermoplastic polymer blend.
- Another suitable class of thermoplastic elastomers are the styrene-ethylene/butylene-styrene block copolymers. These copolymers may additionally comprise a polyolefin (e.g. polypropylene) and a siloxane.
- Thermoplastic elastomeric material may also be selected from one or more of the following: polyester rubbers, polyurethane rubbers, ethylene vinyl acetate rubber, styrene butadiene rubber, copolyether ester TPE, olefinic TPE, polyester amide TPE and polyether amide TPE.
- Other suitable elastomers include ethylene propylene diene rubber (EPDM).
- The EPDM may be present on its own or present as part of a thermoplastic elastomer blend or alloy, e.g. in the form of particles substantially uniformly dispersed in a continuous thermoplastic matrix (e.g. polypropylene or polyethylene). Commercially available thermoplastic elastomer blend and alloys include the SANTOPRENE™ elastomers. Other suitable thermoplastic elastomer blends include butyl-polyethylene (e.g. in a ratio ranging between about 2:3 and about 3:2) and butyl-polypropylene.
- The above-mentioned elastomeric materials can be prepared using methods known to those skilled in the art.
- Preferably, the sealing ring and/or the second sealing ring additionally comprises lubricant material. Suitably, the sealing ring and/or the second sealing ring comprises up to 30%, preferably from 5 to 20% lubricant material.
- Preferably, the stem comprises lubricant material. Suitably, the valve stem comprises up to 30%, preferably from 5 to 20% lubricant material.
- The term ‘lubricant’ herein means any material which reduces friction between the valve stem and seal. Suitable lubricants include silicone oil or a fluorocarbon polymer such as polytetrafluoroethane (PTFE) or fluoroethylene propylene (FEP).
- Lubricant can be applied to the stem, sealing ring or second sealing ring by any suitable process including coating and impregnation, such as by injection or a tamponage process.
- According to another aspect of the present invention, there is provided an aerosol container comprising a valve as described hereinabove.
- Preferably, the aerosol container comprises a suspension of a medicament in a propellant.
- Preferably, the propellant is liquefied HFA134a or HFA-227 or mixtures thereof.
- Preferably, the medicament is selected from albuterol, salmeterol, fluticasone propionate, beclomethasone dipropionate and ipratropium bromide and salts or solvates thereof and any combination thereof.
- The invention will now be described further with reference to the accompanying drawing in which:
- FIG. 1 is a section through a metering valve according to the invention;
- FIG. 2 is a close-up sectional view of a seal-stem contact point in a valve according to the invention;
- FIG. 3 is a close-up sectional view of a seal-stem contact point in a valve according to the invention;
- FIG. 4a is a close-up sectional view of a seal-stem contact point in a prior art valve in a rest position; and
- FIG. 4b is a close-up sectional view of a seal-stem contact point in the valve of FIG. 4a in an active position.
- A valve according to the invention is shown in FIG. 1 and comprises a valve body1 sealed in a
ferrule 2 by means of crimping, the ferrule itself being set on the neck of a container (not shown) with interposition of a gasket 3 in a well-known manner. The container is loadable with a suspension of medicament, such as salmeterol xinafoate in liquid propellant HFA134a. - The valve body1 is formed at its lower part with a
metering chamber 4, and its upper part with a sampling chamber 5 which also acts as a housing for areturn spring 6. The words “upper” and “lower” are used for the container when it is in a use orientation with the neck of the container and valve at the lower end of the container which corresponds to the orientation of the valve as shown in FIG. 1. Inside the valve body 1 is disposed a valve stem 7, apart 8 of which extends outside the valve throughlower stem seal 9 andferrule 2. Thestem part 8 is formed with an inner axial orlongitudinal canal 10 opening at the outer end of the stem and in communication with aradial passage 11. - The upper portion of stem7 has a diameter such that it can pass slidably through an opening in an
upper stem seal 12 and will engage the periphery of that opening sufficiently to provide a seal. The stem seals 9 and 12 are made by a moulding process and have rounded points of contact with the valve stem 7.Upper stem seal 12 is held in position against astep 13 formed in the valve body 1 between the said lower and upper parts by asleeve 14 which defines themetering chamber 4 betweenlower stem seal 9 andupper stem seal 12. The valve stem 7 has apassage 15 which, when the stem is in the inoperative position shown, provides a communication between themetering chamber 4 and sampling chamber 5, which itself communicates with the interior of the container viaorifice 16 formed in the side of the valve body 1. - Valve stem7 is biased downwardly to the inoperative position by
return spring 6 and is provided with ashoulder 17 which abuts againstlower stem seal 9. In the inoperative position as shown in FIG. 1shoulder 17 abuts againstlower stem seal 9 andradial passage 11 opens belowlower stem seal 9 so that themetering chamber 4 is isolated fromcanal 10 and suspension inside cannot escape. - A
ring 18 having a “U” shaped cross section extending in a radial direction is disposed around the valve body beloworifice 16 so as to form atrough 19 around the valve body. As seen in FIG. 1 the ring is formed as a separate component having an inner annular contacting rim of a diameter suitable to provide a friction fit over the upper part of valve body 1, the ring seating againststep 13 below theorifice 16. However, thering 18 may alternatively be formed as an integrally moulded part of valve body 1. - To use the device the container is first shaken to homogenise the suspension within the container. The user then depresses the valve stem7 against the force of the
spring 6. When the valve stem is depressed both ends of thepassage 15 come to lie on the side ofupper stem seal 12 remote from themetering chamber 4. Thus a dose is metered within the metering chamber. Continued depression of the valve stem will move theradial passage 11 into themetering chamber 4 while the upper stem seal 12 seals against the valve stem body. Thus, the metered dose can exit through theradial passage 11 and theoutlet canal 10. - Releasing the valve stem causes it to return to the illustrated position under the force of the
spring 6. Thepassage 15 then once again provides communication between themetering chamber 4 and sampling chamber 5. Accordingly, at this stage liquid passes under pressure from the container throughorifice 16, through thepassage 15 and thence into themetering chamber 4 to fill it. - FIG. 2 shows a cut-away detail of a seal-stem contact point of a valve herein. The upright valve stem108 which has a circular cross-section is sealingly contacted by a sealing
ring 112. Thering aperture 130 of the sealingring 112 has rounded edges. It may be understood that the area of contact of thering 112 with thestem 108 is less than it would be if thering 112 had square-cut edges. When thestem 108 is moved upwards, thering 112 will tend to flex into free-space 140. - FIG. 3 shows a cut-away detail of a seal-stem contact point of a second valve herein. The upright valve stem208 which has a circular cross-section is sealingly contacted by a sealing
ring 212. The ring aperture of the sealingring 212 is edged by tworounded lobes ring 212 with thestem 208 is less than it would be if thering 212 had square-cut edges. When thestem 208 is moved within thering 212, thering 212 will tend to flex into free-space 240 and well 242. The well 242 may be wholly or partially filled with a lubricant material. - FIGS. 4a and 4 b show a cut-away detail of a seal-stem contact point of a prior art valve, wherein FIG. 4a shows a rest configuration and FIG. 4b shows the configuration when the valve is in an active position. The upright valve stem 308 which has a circular cross-section is sealingly contacted by a sealing
ring 312. Thering aperture 330 of the sealingring 312 has square-cut edges 330. When the stem is moved upwards as shown in FIG. 4b, thering 312 is deformed and spreads out such that the area of contact between thering 312 and thestem 308 is increased. The frictional contact between thering 312 and stem is thus, also increased. - It may be appreciated that a number of different configurations of the sealing ring are possible, in addition to those described in FIGS. 2 and 3, in which the contact area between the sealing ring and the valve stem is reduced. One possible configuration is similar to that shown in FIG. 3 but the ring aperture is edged by more than 2 lobes. Another possible configuration has a sealing ring aperture with straight tapered edges leading to a point (such that its cross section is triangular in shape) which has reduced contact with the valve stem compared to straight cut edges. A lobed version of this sealing ring is also possible wherein there are two or more lobes each tapered to a point. A further configuration which reduces the contact area with the valve stem has sections of the top and bottom sides of the ring aperture cut away to leave a smaller projecting portion to form a seal with the valve stem. The projecting portion may have straight cut or shaped edges. Cutting one or more grooves or small channels in the non stem-receiving surfaces of the sealing ring provides space for the stem-receiving part of the sealing ring to move into upon movement of the valve stem, resulting in reduced deformation and friction at the contact surface with the valve stem.
- It may be appreciated that any of the parts of the metering valve which contact the medicament suspension may be coated with materials such as fluoropolymer materials which reduce the tendency of medicament to adhere thereto. Suitable fluoropolymers include polytetrafluoroethylene (PTFE) and fluoroethylene propylene (FEP). Any movable parts may also have coatings applied thereto which enhance their desired movement characteristics. Frictional coatings may therefore be applied to enhance frictional contact and lubricants used to reduce frictional contact as necessary.
- The aerosol container and valve of the invention is suitable for dispensing medicament, particularly for the treatment of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD).
- Appropriate medicaments may thus be selected from, for example, analgesics, e.g., codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g., diltiazem; antiallergics, e.g., cromoglycate, ketotifen or nedocromil; antiinfectives e.g., cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, e.g., methapyrilene; anti-inflammatories, e.g., beclomethasone dipropionate, fluticasone propionate, flunisolide, budesonide, rofleponide, mometasone furoate or triamcinolone acetonide; antitussives, e.g., noscapine; bronchodilators, e.g., albuterol, salmeterol, ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, terbutaline, isoetharine, tulobuterol, or (−)-4-amino-3,5-dichloro-α-[[[6-[2-(2-pyridinyl)ethoxy]hexyl]methyl] benzenemethanol; diuretics, e.g., amiloride; anticholinergics, e.g., ipratropium, tiotropium, atropine or oxitropium; hormones, e.g., cortisone, hydrocortisone or prednisolone; xanthines, e.g., aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; therapeutic proteins and peptides, e.g., insulin or glucagon. It will be clear to a person skilled in the art that, where appropriate, the medicaments may be used in the form of salts, (e.g., as alkali metal or amine salts or as acid addition salts) or as esters (e.g., lower alkyl esters) or as solvates (e.g., hydrates) to optimise the activity and/or stability of the medicament.
- Preferred medicaments are selected from albuterol, salmeterol, fluticasone propionate and beclomethasone dipropionate, and ipratropium bromide and salts or solvates thereof, e.g., the sulphate of albuterol and the xinafoate of salmeterol.
- Medicaments can also be delivered in combinations. Preferred formulations containing combinations of active ingredients contain salbutamol (e.g., as the free base or the sulphate salt) or salmeterol (e.g., as the xinafoate salt) in combination with an anti-inflammatory steroid such as a beclomethasone ester (e.g., the dipropionate) or a fluticasone ester (e.g., the propionate).
- It will be understood that the present disclosure is for the purpose of illustration only and the invention extends to modifications, variations and improvements thereto.
- The application of which this description and claims form part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described therein. They may take the form of product, method or use claims and may include, by way of example and without limitation, one or more of the following claims:
Claims (34)
1. Valve for an aerosol container, the valve comprising a valve body; within said valve body, a sealing ring; and receivable by said sealing ring, a valve stem having a dispensing passage, the valve stem being slidably movable within the sealing ring from a valve-closed position to a valve-open position in which the interior of the valve body is in communication with the dispensing passage, wherein the sealing ring is shaped such as to reduce the contact area between the sealing ring and the valve stem.
2. Valve according to claim 1 , wherein the area of contact between the sealing ring and the valve stem is less than 90% of what the area of contact would be if the sealing ring had square-cut edges.
3. Valve according to either of claims 1 or 2, wherein the sealing ring is formable by a moulding process.
4. Valve according to claim 3 wherein the moulding process is injection moulding.
5. Valve according to claim 3 wherein the moulding process is compression moulding.
6. Valve according to claim 3 wherein the moulding process is transfer moulding.
7. Valve according to any of claims 1 to 6 , wherein the sealing ring is not movable relative to the valve body.
8. Valve according to claim 7 , wherein the sealing ring is held within a cavity in the valve body.
9. Valve according to any of claims 1 to 8 , wherein the stem-receiving part of the sealing ring has at least one rounded edge.
10. Valve according to any of claims 1 to 9 , wherein the stem-receiving part of the sealing ring presents a lobed surface to the stem.
11. Valve according to claim 10 , wherein the lobed surface and the system-receiving part of the stem define one or more wells.
12. Valve according to claim 11 , wherein said one or more wells contain lubricant material therein.
13. Valve according to any of claims 1 to 12 , wherein the valve body has a metering chamber, a sampling chamber and therebetween is provided a second sealing ring within which the stem is slidably movable, the valve stem having a transfer passage such that in the valve-closed position the dispensing passage is isolated from the metering chamber and the metering chamber is in communication with the sampling chamber via said transfer passage, and in the valve-open position the dispensing passage is in communication with the metering chamber and the transfer passage is isolated from the metering chamber, wherein the second sealing ring is shaped such as to reduce the contact area between the second sealing ring and the valve stem.
14. Valve according to claim 13 , wherein the area of contact between the second sealing ring and the valve stem is less than 90% of what the area of contact would be if the second sealing ring had square-cut edges.
15. Valve according to either of claims 13 or 14, wherein the second sealing ring is formable by a moulding process.
16. Valve according to claim 15 wherein the moulding process is injection moulding.
17. Valve according to claim 15 wherein the moulding process is compression moulding.
18. Valve according to claim 15 wherein the moulding process is transfer moulding.
19. Valve according to any of claims 13 to 18 , wherein the second sealing ring is not movable relative to the valve body.
20. Valve according to claim 19 , wherein the second sealing ring is held within a cavity in the valve body.
21. Valve according to any of claims 13 to 20 , wherein the stem-receiving part of the second sealing ring has at least one rounded edge.
22. Valve according to any of claims 13 to 21 , wherein the stem-receiving part of the second sealing ring presents a lobed surface to the stem.
23. Valve according to claim 22 , wherein the lobed surface and the stem-receiving part of the stem define one or more wells.
24. Valve according to claim 23 , wherein said one or more wells contain lubricant material therein.
25. Valve according to any of claims 1 to 24 wherein the sealing ring comprises an elastomeric material.
26. Valve according to any of claims 13 to 25 wherein the second sealing ring comprises an elastomeric material.
27. Valve according to claims 25 and 26 wherein the elastomeric material is selected from the group consisting of
(a) a thermoplastic elastomer comprising a copolymer of about 80 to about 95 mole percent ethylene and a total of about 5 to about 20 percent mole percent of one or more of 1-butene, 1-hexene and 1-octene;
(b) a styrene-ethylene/butylene-styrene block copolymer;
(c) an ethylene propylene diene rubber (EPDM)
(d) a thermoplastic elastomer blend of EPDM dispersed in a polypropylene or polyethylene matrix;
(e) a butyl polyethylene;
(f) a butyl-polypropylene; and any mixtures thereof.
28. Valve according to any of claims 1 to 27 , wherein the sealing ring additionally comprises lubricant material.
29. Valve according to any of claims 13 to 28 , wherein the second sealing ring additionally comprises lubricant material.
30. Valve according to any of claims 1 to 29 , wherein the stem comprises lubricant material.
31. Aerosol container comprising a valve according to any of claims 1 to 30 .
32. Aerosol container according to claim 31 comprising a suspension of a medicament in a propellant.
33. Aerosol container according to claim 32 , wherein, the propellant is liquefied HFA134a or HFA-227 or mixtures thereof.
34. Aerosol container according to either of claims 32 or 33, wherein the medicament is selected from the group consisting of albuterol, salmeterol, fluticasone propionate, beclomethasone dipropionate, ipratropium bromide and salts or solvates thereof and any combination thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/739,664 US20040129737A1 (en) | 1999-03-24 | 2003-12-18 | Valves for use in containers having valve stems slidably movable within round-edged sealing rings |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9906640.9A GB9906640D0 (en) | 1999-03-24 | 1999-03-24 | Valve |
GB9906640.9 | 1999-03-24 | ||
US93723201A | 2001-09-24 | 2001-09-24 | |
US10/739,664 US20040129737A1 (en) | 1999-03-24 | 2003-12-18 | Valves for use in containers having valve stems slidably movable within round-edged sealing rings |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US93723201A Continuation | 1999-03-24 | 2001-09-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040129737A1 true US20040129737A1 (en) | 2004-07-08 |
Family
ID=32684031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/739,664 Abandoned US20040129737A1 (en) | 1999-03-24 | 2003-12-18 | Valves for use in containers having valve stems slidably movable within round-edged sealing rings |
Country Status (1)
Country | Link |
---|---|
US (1) | US20040129737A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2441329A (en) * | 2006-09-04 | 2008-03-05 | Bespak Plc | Seal for a pharmaceutical dispensing device |
US20080087688A1 (en) * | 2004-08-26 | 2008-04-17 | Beshak Plc. | In Metering Valves For Pressurised Dispensing Containers |
US20080230567A1 (en) * | 2005-03-04 | 2008-09-25 | Bespak Plc | Seal For A Dispensing Apparatus |
US20090008584A1 (en) * | 2005-12-27 | 2009-01-08 | Valois Sas | Ring for Aerosol Dispenser Valve |
WO2012151400A3 (en) * | 2011-05-03 | 2013-01-24 | Scholle Corporation | Self sealing bag in box cap assembly |
US20140109900A1 (en) * | 2011-06-15 | 2014-04-24 | 3M Innovative Properties Company | Medicinal inhalation devices, valves and components thereof |
US20140124690A1 (en) * | 2009-02-23 | 2014-05-08 | Josef Karl Kihs | Valve mechanism for controlling release of pressurized fluid |
US20190047778A1 (en) * | 2016-03-23 | 2019-02-14 | Aptar France Sas | Metering valve and fluid product dispensing device comprising such a valve |
US20200071062A1 (en) * | 2017-05-05 | 2020-03-05 | Aptar France Sas | Metering valve and fluid product dispensing device comprising such a valve |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6036942A (en) * | 1993-04-30 | 2000-03-14 | 3M Innovative Properties Company | Seal configuration for aerosol canister |
-
2003
- 2003-12-18 US US10/739,664 patent/US20040129737A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6036942A (en) * | 1993-04-30 | 2000-03-14 | 3M Innovative Properties Company | Seal configuration for aerosol canister |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080087688A1 (en) * | 2004-08-26 | 2008-04-17 | Beshak Plc. | In Metering Valves For Pressurised Dispensing Containers |
US7959042B2 (en) * | 2004-08-26 | 2011-06-14 | Consort Medical Plc | In metering valves for pressurised dispensing containers |
US8129474B2 (en) | 2005-03-04 | 2012-03-06 | Consort Medical Plc | Seal for a dispensing apparatus |
US20080230567A1 (en) * | 2005-03-04 | 2008-09-25 | Bespak Plc | Seal For A Dispensing Apparatus |
US20090008584A1 (en) * | 2005-12-27 | 2009-01-08 | Valois Sas | Ring for Aerosol Dispenser Valve |
US8286941B2 (en) * | 2005-12-27 | 2012-10-16 | Aptar France Sas | Ring for aerosol dispenser valve |
US20100000524A1 (en) * | 2006-09-04 | 2010-01-07 | Consort Medical Plc | Seal for a dispensing apparatus |
US8110633B2 (en) | 2006-09-04 | 2012-02-07 | Consort Medical Plc | Seal for a dispensing apparatus |
GB2441329B (en) * | 2006-09-04 | 2011-06-29 | Bespak Plc | Seal for a dispensing apparatus |
GB2441329A (en) * | 2006-09-04 | 2008-03-05 | Bespak Plc | Seal for a pharmaceutical dispensing device |
US20140124690A1 (en) * | 2009-02-23 | 2014-05-08 | Josef Karl Kihs | Valve mechanism for controlling release of pressurized fluid |
US9188232B2 (en) * | 2009-02-23 | 2015-11-17 | Josef Karl Kihs | Valve mechanism for controlling release of pressurized fluid |
WO2012151400A3 (en) * | 2011-05-03 | 2013-01-24 | Scholle Corporation | Self sealing bag in box cap assembly |
US20140109900A1 (en) * | 2011-06-15 | 2014-04-24 | 3M Innovative Properties Company | Medicinal inhalation devices, valves and components thereof |
US20190047778A1 (en) * | 2016-03-23 | 2019-02-14 | Aptar France Sas | Metering valve and fluid product dispensing device comprising such a valve |
US10745189B2 (en) * | 2016-03-23 | 2020-08-18 | Aptar France Sas | Metering valve and fluid product dispensing device comprising such a valve |
US20200071062A1 (en) * | 2017-05-05 | 2020-03-05 | Aptar France Sas | Metering valve and fluid product dispensing device comprising such a valve |
US10968033B2 (en) * | 2017-05-05 | 2021-04-06 | Aptar France Sas | Metering valve and fluid product dispensing device comprising such a valve |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1200321B1 (en) | Valve with a valve stem wiper | |
US7383970B2 (en) | Valve with a two-component seal | |
US6474513B2 (en) | Valve for aerosol container | |
AU744384B2 (en) | Valve for aerosol container | |
EP1144272B1 (en) | Valve | |
EP1324796A1 (en) | Medicament dispenser | |
US20040129737A1 (en) | Valves for use in containers having valve stems slidably movable within round-edged sealing rings | |
US20040223916A1 (en) | Canister for a metered dose inhaler | |
MXPA99011752A (en) | Valve for aerosol container | |
MXPA99011989A (en) | Valve for aerosol container |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |